Top Page
Inspire Veterinary Partners, Inc. Class A
(NASDAQ:IVP)
Inspire Veterinary Partners, Inc. Class A (IVP) vs. SPDR S&P 500 ETF (SPY)
Inspire Veterinary Partners, Inc. Class A Business Overview & Revenue Model
Inspire Veterinary Partners, Inc. Class A Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.56M | 16.59M | 16.68M | 9.83M | 2.55M | 0.00 |
| Gross Profit | 4.73M | 3.29M | 3.55M | 2.55M | 829.29K | 0.00 |
| EBITDA | -8.36M | -9.50M | -10.84M | -2.91M | -977.46K | 0.00 |
| Net Income | -11.94M | -14.26M | -14.79M | -4.91M | -1.33M | -5.52K |
Balance Sheet | ||||||
| Total Assets | 23.96M | 20.20M | 21.79M | 20.19M | 6.33M | 21.97K |
| Cash, Cash Equivalents and Short-Term Investments | 341.75K | 523.69K | 178.96K | 444.25K | 2.06M | 21.97K |
| Total Debt | 13.94M | 16.37M | 18.42M | 23.61M | 6.69M | 0.00 |
| Total Liabilities | 19.79M | 18.63M | 22.58M | 25.32M | 7.20M | 0.00 |
| Stockholders Equity | 4.17M | 1.56M | -788.26K | -5.14M | -869.09K | 21.97K |
Cash Flow | ||||||
| Free Cash Flow | -4.34M | -10.24M | -4.20M | -2.84M | -2.32M | -5.52K |
| Operating Cash Flow | -4.23M | -10.01M | -3.82M | -2.66M | -1.01M | -5.52K |
| Investing Cash Flow | -1.96M | -237.98K | -1.87M | -14.67M | -4.02M | 0.00 |
| Financing Cash Flow | 5.89M | 10.59M | 5.63M | 15.71M | 7.07M | 269.16K |
Inspire Veterinary Partners, Inc. Class A Technical Analysis
Inspire Veterinary Partners, Inc. Class A Risk Analysis
Inspire Veterinary Partners, Inc. Class A Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
58 Neutral | $13.83M | 4.78 | 48.22% | ― | 13.71% | ― | |
40 Neutral | $63.60M | -0.02 | -1.75% | ― | -2.53% | 99.45% | |
39 Underperform | $2.27M | -0.12 | ― | ― | -12.74% | 13.22% | |
38 Underperform | $1.68M | >-0.01 | -331.80% | ― | -8.76% | 99.64% |
Inspire Veterinary Partners, Inc. Class A Corporate Events
On January 9, 2026, Inspire Veterinary Partners, Inc. filed a Certificate of Amendment in Nevada to significantly increase its authorized Class A common stock from 100 million to 700 million shares, while leaving authorized Class B common stock and preferred stock unchanged. The move, approved by the board and stockholders with sufficient voting power, materially expands the company’s equity capacity, potentially enabling future capital-raising, acquisitions, or other strategic initiatives that could affect the ownership structure and dilution risk for existing shareholders.
The most recent analyst rating on (IVP) stock is a Hold with a $0.04 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
On January 6, 2026, effective as of December 31, 2025, Inspire Veterinary Partners, Inc. entered into a securities purchase agreement with Manetto Hill Fund Series I LLC under which it may issue up to $1.626 million in convertible promissory notes, and concurrently issued a secured convertible note of $975,000 in principal for $750,000 in proceeds, carrying 10% annual interest and maturing on December 31, 2026, with up to 2.5 million commitment shares and a variable conversion price tied to the company’s trading price; the note is secured by a first-priority lien on certain veterinary clinics, includes restrictive covenants on asset sales and future financings, and the company plans to use the funds mainly for working capital and acquisitions while registering the resale of the conversion and commitment shares. Also on January 6, 2026, board member Timothy Watters resigned effective immediately, with the company stating that his departure did not result from any disagreement over its operations, policies, or practices.
The most recent analyst rating on (IVP) stock is a Hold with a $0.04 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
On December 18, 2025, Inspire Veterinary Partners, Inc. entered into a Cancellation and Exchange Agreement with Target Capital 1 LLC under which the company agreed to cancel $150,000 of principal outstanding under a June 10, 2025 promissory note in exchange for issuing 3,000,000 shares of its Class A common stock, valued at $0.05 per share. The private, exempt debt-for-equity swap reduces Inspire’s debt load while diluting existing shareholders, reflecting a balance-sheet-focused capital structure move that may improve liquidity and financial flexibility but alters the company’s ownership mix and could affect investor perceptions of its financing strategy.
The most recent analyst rating on (IVP) stock is a Sell with a $0.04 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
On December 12, 2025, Inspire Veterinary Partners, Inc. entered a Consulting Agreement with 622 Capital LLC to receive business development services aimed at business financing opportunities. As part of this agreement, the company will issue an aggregate of 9,450,000 shares of its Class A common stock to the consultant, impacting the company’s equity structure. The agreement will remain effective under standard provisions until terminated, reflecting efforts to enhance Inspire Veterinary Partners’ financial positioning and strategic growth.
The most recent analyst rating on (IVP) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
On December 10, 2025, Inspire Veterinary Partners, Inc. held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The stockholders elected directors to the board for terms expiring at the 2026 annual meeting, and ratified the appointment of M&K CPAS, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to influence the company’s strategic direction and financial management.
The most recent analyst rating on (IVP) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
Inspire Veterinary Partners, Inc. announced on December 1, 2025, a reduction in the Floor Price of its Series B Convertible Preferred Stock from $0.1879 to $0.05 per share, following agreements with accredited investors. Additionally, the company redeemed 2,027 shares of Series B Preferred Stock for approximately $2.7 million. On December 4, 2025, the company also amended promissory notes with Target Capital 1 LLC to lower the Floor Price and restrict conversion to prevent exceeding 4.99% ownership of the company’s Class A common stock.
The most recent analyst rating on (IVP) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
Inspire Veterinary Partners, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, threatening suspension and delisting of its securities. The company has requested a hearing, scheduled for January 13, 2026, to appeal this decision, but there is no assurance of a favorable outcome.
The most recent analyst rating on (IVP) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
On November 13, 2025, Inspire Veterinary Partners, Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement due to its stock’s performance over the past 30 days. As a result, the company’s securities are set to be suspended from trading on November 24, 2025, unless an appeal is requested by November 20, 2025. The company plans to appeal, which will delay the suspension or delisting process, but there is no guarantee of a favorable outcome.
The most recent analyst rating on (IVP) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.
On November 5, 2025, Inspire Veterinary Partners, Inc. issued Senior Convertible Promissory Notes to Keystone Capital Partners, LLC and Seven Knots, LLC, each with a principal amount of $178,571.43. The notes, which mature on August 5, 2026, include a 10% annual interest rate and are convertible into the company’s Class A common stock. This financial maneuver is aimed at bolstering the company’s working capital, with specific terms allowing for conversion and prepayment under certain conditions, potentially impacting the company’s financial strategy and shareholder structure.
The most recent analyst rating on (IVP) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Inspire Veterinary Partners, Inc. Class A stock, see the IVP Stock Forecast page.